search
Back to results

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Glimepiride
Canagliflozin (JNJ-28431754)
Metformin
Sponsored by
Janssen Research & Development, LLC
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2 focused on measuring Diabetes, Metformin, Glimepiride, Hemoglobin A1c, Type 2 diabetes mellitus, Canagliflozin

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must have a diagnosis of type 2 diabetes
  • Body mass index (BMI) >=22 to <=45 kg/m2, at screening
  • Patients must be taking a stable dosage of metformin as monotherapy at screening
  • Patients must have a HbA1c between >=7% and <=9.5% at Week 2
  • Patients must have a fasting plasma glucose (FPG) <=270 mg/dL (15 mmol/L) at Week -2

Exclusion Criteria:

  • Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin
  • History of diabetic ketoacidosis or type 1 diabetes mellitus
  • History of pancreas or beta-cell transplantation
  • History of active proliferative diabetic retinopathy
  • History of hereditary glucose-galactose malabsorption or primary renal glucosuria
  • Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant
  • Taken thiazolidinedione therapy in the past 16 weeks before screening

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

Experimental

Arm Label

Glimepiride

Canagliflozin 100 mg

Canagliflozin 300 mg

Arm Description

Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.

Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.

Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.

Outcomes

Primary Outcome Measures

Change in HbA1c From Baseline to Week 52
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.

Secondary Outcome Measures

Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52
The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.
Percent Change in Body Weight From Baseline to Week 52
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.
Change in HbA1c From Baseline to Week 104
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.

Full Information

First Posted
August 28, 2009
Last Updated
December 1, 2016
Sponsor
Janssen Research & Development, LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT00968812
Brief Title
CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
Official Title
A Randomized, Double-Blind, 3-Arm Parallel-Group, 2-Year (104-Week), Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-28431754 Compared With Glimepiride in the Treatment of Subjects With Type 2 Diabetes Mellitus Not Optimally Controlled on Metformin Monotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
December 2016
Overall Recruitment Status
Completed
Study Start Date
September 2009 (undefined)
Primary Completion Date
December 2011 (Actual)
Study Completion Date
January 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Janssen Research & Development, LLC

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to demonstrate the efficacy, safety, and tolerability of canagliflozin (JNJ-28431754) compared with glimepiride in patients with type 2 diabetes mellitus with inadequate control despite treatment with metformin.
Detailed Description
Type 2 diabetes mellitus (T2DM) is well recognized as a major public health problem that presents patients with a significant risk of complications including heart disease, retinopathy, nephropathy, and neuropathy. Various classes of orally administered antihyperglycemic agents have been developed for the treatment of diabetes and although individual agents may be highly effective for some patients, it is still difficult to maintain optimal glycemic control in most patients, thereby resulting in high rates of morbidity and mortality in the diabetic population. This is a randomized, double-blind, active comparator-controlled, 3-arm, parallel-group, multicenter study to demonstrate the efficacy, safety, and tolerability of canagliflozin compared with a sulfonylurea (glimepiride) in patients with T2DM, 18 to 80 years of age, inclusive, who are not optimally controlled on metformin monotherapy. The primary study hypothesis is that the study drug will be non-inferior to glimepiride as assessed by the change in hemoglobin A1c (HbA1c) from baseline. The patients will receive capsules taken by mouth of canagliflozin (either 100 or 300 mg), or glimepiride with a starting dosage of 1 mg, which will be increased to a maximum dose of 6 or 8 mg once daily for a total duration of 104 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
Keywords
Diabetes, Metformin, Glimepiride, Hemoglobin A1c, Type 2 diabetes mellitus, Canagliflozin

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1452 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Glimepiride
Arm Type
Active Comparator
Arm Description
Each patient will receive glimepiride, at protocol-specified doses, once daily in combination with protocol-specified doses of metformin for 104 weeks.
Arm Title
Canagliflozin 100 mg
Arm Type
Experimental
Arm Description
Each patient will receive 100 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
Arm Title
Canagliflozin 300 mg
Arm Type
Experimental
Arm Description
Each volunteer will receive 300 mg of canagliflozin (JNJ-28431754) once daily with protocol-specified doses of metformin for 104 weeks.
Intervention Type
Drug
Intervention Name(s)
Glimepiride
Other Intervention Name(s)
sulfonylurea
Intervention Description
Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
Intervention Type
Drug
Intervention Name(s)
Canagliflozin (JNJ-28431754)
Intervention Description
Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
Intervention Type
Drug
Intervention Name(s)
Metformin
Intervention Description
Metformin will be given orally at the protocol-specified dose for 104 weeks.
Primary Outcome Measure Information:
Title
Change in HbA1c From Baseline to Week 52
Description
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.
Time Frame
Day 1 (Baseline) and Week 52
Secondary Outcome Measure Information:
Title
Percentage of Patients Experiencing at Least 1 Hypoglycemic Event From Baseline to Week 52
Description
The table below shows the percentage of patients who experienced at least 1 documented hypoglycemic event from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in percentages.
Time Frame
Day 1 (Baseline) and Week 52
Title
Percent Change in Body Weight From Baseline to Week 52
Description
The table below shows the least-squares (LS) mean percent change in body weight from Baseline to Week 52 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean percent change.
Time Frame
Day 1 (Baseline) and Week 52
Title
Change in HbA1c From Baseline to Week 104
Description
The table below shows the least-squares (LS) mean change in HbA1c from Baseline to Week 104 for each treatment group. The statistical analyses show the treatment differences (ie, each canagliflozin group minus glimepiride) in the LS mean change.
Time Frame
Baseline, Week 104

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have a diagnosis of type 2 diabetes Body mass index (BMI) >=22 to <=45 kg/m2, at screening Patients must be taking a stable dosage of metformin as monotherapy at screening Patients must have a HbA1c between >=7% and <=9.5% at Week 2 Patients must have a fasting plasma glucose (FPG) <=270 mg/dL (15 mmol/L) at Week -2 Exclusion Criteria: Patients having prior exposure or known contraindication or suspected hypersensitivity to JNJ-28431754, glimepiride, or metformin History of diabetic ketoacidosis or type 1 diabetes mellitus History of pancreas or beta-cell transplantation History of active proliferative diabetic retinopathy History of hereditary glucose-galactose malabsorption or primary renal glucosuria Renal disease requiring treatment with immunosuppressive therapy within the past 12 months before screening or a history of dialysis or renal transplant Taken thiazolidinedione therapy in the past 16 weeks before screening
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Janssen Research & Development, LLC Clinical Trial
Organizational Affiliation
Janssen Research & Development, LLC
Official's Role
Study Director
Facility Information:
City
Calera
State/Province
Alabama
Country
United States
City
Gilbert
State/Province
Arizona
Country
United States
City
Mesa
State/Province
Arizona
Country
United States
City
Tucson
State/Province
Arizona
Country
United States
City
Jonesboro
State/Province
Arkansas
Country
United States
City
Buena Park
State/Province
California
Country
United States
City
Encinitas
State/Province
California
Country
United States
City
Fresno
State/Province
California
Country
United States
City
Lincoln
State/Province
California
Country
United States
City
Roseville
State/Province
California
Country
United States
City
San Diego
State/Province
California
Country
United States
City
Westlake Village
State/Province
California
Country
United States
City
Chipley
State/Province
Florida
Country
United States
City
Marianna
State/Province
Florida
Country
United States
City
Oldsmar
State/Province
Florida
Country
United States
City
Orlando
State/Province
Florida
Country
United States
City
Augusta
State/Province
Georgia
Country
United States
City
Perry
State/Province
Georgia
Country
United States
City
Nampa
State/Province
Idaho
Country
United States
City
Chicago
State/Province
Illinois
Country
United States
City
Vernon Hills
State/Province
Illinois
Country
United States
City
Valparaiso
State/Province
Indiana
Country
United States
City
New Orleans
State/Province
Louisiana
Country
United States
City
Elkridge
State/Province
Maryland
Country
United States
City
Bloomfield Hills
State/Province
Michigan
Country
United States
City
Las Vegas
State/Province
Nevada
Country
United States
City
Canal Fulton
State/Province
Ohio
Country
United States
City
Gallipolis
State/Province
Ohio
Country
United States
City
Mason
State/Province
Ohio
Country
United States
City
Perrysburg
State/Province
Ohio
Country
United States
City
Tulsa
State/Province
Oklahoma
Country
United States
City
Yukon
State/Province
Oklahoma
Country
United States
City
Fleetwood
State/Province
Pennsylvania
Country
United States
City
Greenville
State/Province
South Carolina
Country
United States
City
Nashville
State/Province
Tennessee
Country
United States
City
Houston
State/Province
Texas
Country
United States
City
Odessa
State/Province
Texas
Country
United States
City
Pearland
State/Province
Texas
Country
United States
City
San Antonio
State/Province
Texas
Country
United States
City
Danville
State/Province
Virginia
Country
United States
City
Olympia
State/Province
Washington
Country
United States
City
Milwaukee
State/Province
Wisconsin
Country
United States
City
Wauwatosa
State/Province
Wisconsin
Country
United States
City
Buenos Aires
Country
Argentina
City
Ciudad Autonoma De Buenos Aires
Country
Argentina
City
Mar Del Plata
Country
Argentina
City
Rosario
Country
Argentina
City
Dimitrovgrad
Country
Bulgaria
City
Kazanlak
Country
Bulgaria
City
Rousse
Country
Bulgaria
City
Sofia
Country
Bulgaria
City
Chilliwack
State/Province
British Columbia
Country
Canada
City
Kelowna
State/Province
British Columbia
Country
Canada
City
Vancouver
State/Province
British Columbia
Country
Canada
City
St. John'S
State/Province
Newfoundland and Labrador
Country
Canada
City
Mississauga
State/Province
Ontario
Country
Canada
City
Toronto
State/Province
Ontario
Country
Canada
City
Saskatoon
State/Province
Saskatchewan
Country
Canada
City
Quebec
Country
Canada
City
San Jose
Country
Costa Rica
City
San Pedro
Country
Costa Rica
City
Aalborg
Country
Denmark
City
Ballerup
Country
Denmark
City
Vejle
Country
Denmark
City
Vipperoed
Country
Denmark
City
Helsinki
Country
Finland
City
Kokkola
Country
Finland
City
Kuopio
Country
Finland
City
Oulu
Country
Finland
City
Turku
Country
Finland
City
Berlin
Country
Germany
City
Dresden
Country
Germany
City
Duesseldorf
Country
Germany
City
Hamburg
Country
Germany
City
Mainz
Country
Germany
City
Villingen-Schwenningen
Country
Germany
City
Bangalore
Country
India
City
Chennai
Country
India
City
Coimbatore
Country
India
City
Hyderabad
Country
India
City
Nagpur
Country
India
City
Pune
Country
India
City
Wardha
Country
India
City
Beer Sheba
Country
Israel
City
Haifa
Country
Israel
City
Holon
Country
Israel
City
Jerusalem
Country
Israel
City
Ramat Gan
Country
Israel
City
Rehovot
Country
Israel
City
Tel Aviv
Country
Israel
City
Tel-Aviv
Country
Israel
City
Zefat
Country
Israel
City
Daegu
Country
Korea, Republic of
City
Goyang-Si
Country
Korea, Republic of
City
Gyeonggi-Do
Country
Korea, Republic of
City
Incheon
Country
Korea, Republic of
City
Seoul
Country
Korea, Republic of
City
Suwon
Country
Korea, Republic of
City
Wonju-Si
Country
Korea, Republic of
City
Wonju
Country
Korea, Republic of
City
Ciudad De Mexico
Country
Mexico
City
Mexico
Country
Mexico
City
Monterrey
Country
Mexico
City
Alesund
Country
Norway
City
Oslo
Country
Norway
City
Cebu
Country
Philippines
City
Marikina City
Country
Philippines
City
Pasay
Country
Philippines
City
Quezon City
Country
Philippines
City
Bydgoszcz
Country
Poland
City
Krakow
Country
Poland
City
Kutno 001
Country
Poland
City
Lodz
Country
Poland
City
Lublin
Country
Poland
City
Torun
Country
Poland
City
Warszawa
Country
Poland
City
Wroclaw
Country
Poland
City
Zielona Gora
Country
Poland
City
Ponce
Country
Puerto Rico
City
Baia Mare
Country
Romania
City
Brasov
Country
Romania
City
Bucharest
Country
Romania
City
Cluj
Country
Romania
City
Galati
Country
Romania
City
Ploiesti
Country
Romania
City
Targu Mures
Country
Romania
City
Arkhangelsk
Country
Russian Federation
City
Moscow
Country
Russian Federation
City
Saint Petersburg
Country
Russian Federation
City
Samara
Country
Russian Federation
City
Saratov
Country
Russian Federation
City
St Petersburg
Country
Russian Federation
City
Banska Bystrica
Country
Slovakia
City
Bratislava
Country
Slovakia
City
Lubochna
Country
Slovakia
City
Presov
Country
Slovakia
City
Dnepropetrovsk
Country
Ukraine
City
Kharkov
Country
Ukraine
City
Kiev
Country
Ukraine
City
Poltava
Country
Ukraine
City
Ternopil
Country
Ukraine
City
Vinnitsa
Country
Ukraine

12. IPD Sharing Statement

Citations:
PubMed Identifier
31001673
Citation
Heerspink HJL, Perco P, Mulder S, Leierer J, Hansen MK, Heinzel A, Mayer G. Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. 2019 Jul;62(7):1154-1166. doi: 10.1007/s00125-019-4859-4. Epub 2019 Apr 17.
Results Reference
derived
PubMed Identifier
29452178
Citation
Garvey WT, Van Gaal L, Leiter LA, Vijapurkar U, List J, Cuddihy R, Ren J, Davies MJ. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018 Aug;85:32-37. doi: 10.1016/j.metabol.2018.02.002. Epub 2018 Feb 13.
Results Reference
derived
PubMed Identifier
27977934
Citation
Qiu R, Balis D, Xie J, Davies MJ, Desai M, Meininger G. Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis. Curr Med Res Opin. 2017 Mar;33(3):553-562. doi: 10.1080/03007995.2016.1271780. Epub 2017 Jan 4.
Results Reference
derived
PubMed Identifier
27600862
Citation
John M, Cerdas S, Violante R, Deerochanawong C, Hassanein M, Slee A, Canovatchel W, Hamilton G. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates. Int J Clin Pract. 2016 Sep;70(9):775-85. doi: 10.1111/ijcp.12868.
Results Reference
derived
PubMed Identifier
27495291
Citation
Patel CA, Bailey RA, Vijapurkar U, Meininger G, Blonde L. A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures. BMC Health Serv Res. 2016 Aug 5;16(a):356. doi: 10.1186/s12913-016-1607-z.
Results Reference
derived
PubMed Identifier
27002421
Citation
Blonde L, Stenlof K, Fung A, Xie J, Canovatchel W, Meininger G. Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks. Postgrad Med. 2016 May;128(4):371-80. doi: 10.1080/00325481.2016.1169894. Epub 2016 Apr 7.
Results Reference
derived
PubMed Identifier
26984361
Citation
Leiter LA, Langslet G, Vijapurkar U, Davies MJ, Canovatchel W. Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin. Diabetes Ther. 2016 Jun;7(2):269-78. doi: 10.1007/s13300-016-0163-1. Epub 2016 Mar 16.
Results Reference
derived
PubMed Identifier
26580237
Citation
Watts NB, Bilezikian JP, Usiskin K, Edwards R, Desai M, Law G, Meininger G. Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2016 Jan;101(1):157-66. doi: 10.1210/jc.2015-3167. Epub 2015 Nov 18.
Results Reference
derived
PubMed Identifier
26579834
Citation
Lavalle-Gonzalez FJ, Eliaschewitz FG, Cerdas S, Chacon Mdel P, Tong C, Alba M. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America. Curr Med Res Opin. 2016;32(3):427-39. doi: 10.1185/03007995.2015.1121865. Epub 2016 Jan 14.
Results Reference
derived
PubMed Identifier
25205142
Citation
Leiter LA, Yoon KH, Arias P, Langslet G, Xie J, Balis DA, Millington D, Vercruysse F, Canovatchel W, Meininger G. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study. Diabetes Care. 2015 Mar;38(3):355-64. doi: 10.2337/dc13-2762. Epub 2014 Sep 9.
Results Reference
derived
PubMed Identifier
24517339
Citation
Nyirjesy P, Sobel JD, Fung A, Mayer C, Capuano G, Ways K, Usiskin K. Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies. Curr Med Res Opin. 2014 Jun;30(6):1109-19. doi: 10.1185/03007995.2014.890925. Epub 2014 Feb 21.
Results Reference
derived
PubMed Identifier
23850055
Citation
Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013 Sep 14;382(9896):941-50. doi: 10.1016/S0140-6736(13)60683-2. Epub 2013 Jul 12.
Results Reference
derived

Learn more about this trial

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride

We'll reach out to this number within 24 hrs